ai
Cont

R_1 is methyl, R_2 is carboxybenzyl, C_3 is the R configuration, and R_3 is hydrogen or $-CO(NH)OCH_3$, R_4 is hydrogen.

REMARKS

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

For the reasons set forth in the accompanying renewed petition, the petitioners hereby respectfully request the Patent Office withdraw the requirement for restriction and an early and favorable action on the merits on all pending claims in the application.

Should the Patent Office wish to discuss the foregoing, or any matter of form in an effort to advance this application toward allowance, the Patent Office is urged to telephone the undersigned at the indicated number.

Respectfully submitted,

MARSHALL, GERSTEIN, & BORUN
6300 Sears Tower
233 S. Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300
Attorneys for Applicant

By: _____
Mark H. Hopkins, Agent
Registration No. 44,775

July 3, 2002

Version with markings to show changes made."

In the claims:

Please add new claim 13 as shown below:

13. (New) A compound of the following structural formula:



and pharmaceutically acceptable salts thereof wherein;

R_1 and R_2 are independently hydrogen, C_{1-6}alkyl, or carboxybenzyl or R_1 and R_2 are joined to form pyrrolidine, piperidine, morpholine or imidazole;

R_3 and R_4 are joined to form an X-substituted-imidazolin-2-one, -CONX-, when C_3 is either the R- or S-configuration;

X is OCH_3, SO_2R_5, SO_2CF_3, or CN;

R_5 is C_{1-6} alkyl or a C_{5-10} aromatic ring (optionally substituted with a halogen or hydroxyl); and

Y is hydrogen, Cl, Br, F, CN, $CONR_1R_2$, CF_3, OCH_3, $SO_2NR_1R_2$; and if

R_1 is hydrogen, R_2 is methyl, and C_3 is the R-configuration, R_3 and R_4 are hydrogen; and if

R_1 is methyl, R_2 is carboxybenzyl, C_3 is the R-configuration, and R_3 is hydrogen or $-CO(NH)OCH_3$, R_4 is hydrogen.